Clinical Trial Update: Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for switching virologically suppressed HIV-1 adults to dolutegravir plus lamivudine (TANGO) with completed results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Dolutegravir plus lamivudine (dolutegravir; lamivudine)

Snippet

Sponsor: ViiV Healthcare | Conditions: HIV Infections | Phase 3 | Status: COMPLETED | Results posted: 2020-06-02